Alto Neuroscience Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-12.3%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$2.95next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 11 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash Runway Quarterly264MTarget: Sufficient to fund operations through 2029
ALTO-300 Phase 2b MDD Trial EnrollmentTarget: Complete enrollment of biomarker-positive patients
ALTO-100 Phase 2b BPD Trial Enrollment QuarterlyTarget: Complete enrollment of biomarker-characterized patients
Watch Items
- ALTO-300 Phase 2b MDD Topline DataTrigger: Mid-2026 readoutAction: Evaluate primary endpoint (MADRS change from baseline) in the EEG biomarker-positive group to determine registrational path.
- ALTO-100 Phase 2b BPD Topline DataTrigger: Second half of 2026 readoutAction: Assess efficacy on MADRS in patients characterized by a cognitive biomarker to validate the neuroplasticity mechanism.
- ALTO-207 Phase 2b TRD Trial InitiationTrigger: First half of 2026 initiationAction: Monitor site activation and patient recruitment progress for the 178-patient study.
Research as of 19 Jun 2026